This clinical trial is a two-arm, open-label, single-sequence, multiple oral dosings, cross-over design clinical trial to evaluate the safety and pharmacokinetic characteristics of HL1113-R1 and HL1113-R2 in healthy adult volunteers

Inclusion Criteria:

• Healthy adult subjects aged ≥19 years at the time of screening
• Subjects with no clinically significant congenital or chronic diseases based on screening, and no clinically significant findings on internal medicine examination (including, if necessary, electroencephalogram [EEG], electrocardiogram [ECG], chest examination, upper gastrointestinal endoscopy, or gastrointestinal radiography)
• etc.

Exclusion Criteria:

• Subjects who have received medications known to markedly induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 30 days prior to the screening visit
• Subjects who have received any medications that may affect the outcome of the study within 10 days prior to the screening visit
• etc.